Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-24T06:57:47.408Z Has data issue: false hasContentIssue false
  • English
  • Français

Defining Response and Remission in Anxiety Disorders: Toward an Integrated Approach

Published online by Cambridge University Press:  07 November 2014

Borwin Bandelow
Borwin Bandelow*
Affiliation:
Dr. Bandelow is in the Department of Psychiatry and Psychotherapy at the, University of Göttingen in Germany
*
Borwin Bandelow, MD, Department of Psychiatry and Psychotherapy, University of Göttingen, von-Siebold-Str. 5, D-37085 Göttingen, Germany. Tel: +49-551-396607; Fax +49-551-392004; E-mail: Sekretariat-Bandelow@medizin.uni-goettingen.de
Get access Rights & Permissions [Opens in a new window]

Abstract

Response and remission rates are commonly used to evaluate the efficacy of treatments for anxiety disorders and other psychiatric illnesses. Response is generally regarded as a clinically meaningful improvement in symptoms, while remission, the goal of treatment, is generally thought of as the absence or near absence of symptoms following illness, accompanied by a return to premorbid levels of functioning. Response and remission are often defined using psychiatric rating scales, based on score cutoffs or the magnitude of score changes from baseline. While no universally accepted criteria exist, a commonly used threshold for response is a >50% improvement in the total score, while for remission, various cutoff points have been used. Comparison of cutoffs or change scores for disease-specific scales with Clinical Global Impressions ratings is a useful way of evaluating response and remission criteria across disorders. To illustrate the use of disease-specific and global measures, this article summarizes data from randomized, placebo-controlled studies of adult patients with generalized anxiety disorder, social anxiety disorder, or panic disorder treated with the serotonin norepinephrine reuptake inhibitor venlafaxine extended release, for which acute-phase data are available (a total of 13 trials).

Type
Research Article
Information
CNS Spectrums , Volume 11 , Issue S12 , 2006 , pp. 21 - 28
Copyright
Copyright © Cambridge University Press 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.ECDEU Assessment Manual for Psychopharmacology. rev. Guy, W, ed. (1976) National Institute of Mental Health, Psychopharmacology Research Branch: Rockville, MD; 1976.Google Scholar
2.Hamilton, M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50–55.CrossRefGoogle ScholarPubMed
3.Liebowitz, MR. Social phobia. Mod Probl Pharmacopsychiatry. 1987;22:141–173.CrossRefGoogle ScholarPubMed
4.Bandelow, B. Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale. Int Clin Psychopharmacol. 1995;10:73–81.CrossRefGoogle ScholarPubMed
5.Shear, MK, Brown, TA, Barlow, DH, et al.Multicenter collaborative panic disorder severity scale. Am J Psychiatry. 1997;154:1571–1575.CrossRefGoogle ScholarPubMed
6. European Medicines Agency Committee for Medical Products for Human Use: Guideline on clinical investigation of medical products indicated for the treatment of panic disorder. Available at: http://www.emea.eu.int/pdfs/human/ewp/428002.en.pdf. Accessed August 17, 2006.Google Scholar
7.Jaeschke, R, Singer, J, Guyatt, GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10:407–415.CrossRefGoogle ScholarPubMed
8.Juniper, EF, Guyatt, GH, Willan, A, Griffith, LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol. 1994;47:81–87.CrossRefGoogle Scholar
9.Furukawa, TA, Jaeschke, R, Cook, D, Guyatt, G. Measurements of Patients' Discomfort, Distress and Disability: Users' Guide to the Medical Literature. Chicago, Ill: American Medical Association Press; 2006.Google Scholar
10.Jacobson, NS, Truax, P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol. 1991;59:12–19.CrossRefGoogle ScholarPubMed
11.Ballenger, JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry. 1999;60(suppl 22):29–34.Google ScholarPubMed
12.Doyle, AC, Pollack, MH. Establishment of remission criteria for anxiety disorders. J Clin Psychiatry. 2003;64(suppl 15):40–45.Google ScholarPubMed
13.Pollack, MH, Meoni, P, Otto, MW, Hackett, D. Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long-term studies. J Clin Psychopharmacol. 2003;23:250–259.CrossRefGoogle ScholarPubMed
14.Rickels, K, Zaninelli, R, McCafferty, J, Bellew, K, Iyengar, M, Sheehan, D. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2003;160:749–756.CrossRefGoogle ScholarPubMed
15.Zimmerman, M, Posternak, MA, Chelminski, I. Is the cutoff to define remission on the Hamilton Rating Scale for Depression too high? J Nerv Ment Dis. 2005;193:170–175.CrossRefGoogle ScholarPubMed
16.Allgulander, C, Hackett, D, Salinas, E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry. 2001;179:15–22.CrossRefGoogle Scholar
17.Davidson, JR, DuPont, RL, Hedges, D, Haskins, JT. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry. 1999;60:528–535.CrossRefGoogle ScholarPubMed
18.Gelenberg, AJ, Lydiard, RB, Rudolph, RL, Aguiar, L, Haskins, JT, Salinas, E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA. 2000;283:3082–3088.CrossRefGoogle ScholarPubMed
19.Hackett, D, Haudiquet, V, Salinas, E. A method for controlling for a high placebo response rate in a comparison of venlafaxine XR and diazepam in the short-term treatment of patients with generalised anxiety disorder. Eur Psychiatry. 2003;18:182–187.CrossRefGoogle Scholar
20.Rickels, K, Pollack, MH, Sheehan, DV, Haskins, JT. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry. 2000;157:968–974.CrossRefGoogle ScholarPubMed
21.Allgulander, C, Mangano, R, Zhang, J, et al.Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol. 2004;19:387–396.CrossRefGoogle Scholar
22.Liebowitz, MR, Gelenberg, AJ, Munjack, D. Venlafaxine vs paroxetine in social anxiety disorder. Arch Gen Psychiatry. 2005;62:190–198.CrossRefGoogle ScholarPubMed
23.Liebowitz, MR, Mangano, RM, Bradwejn, J, Asnis, G. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry. 2005;66:238–247.CrossRefGoogle ScholarPubMed
24.Rickels, K, Mangano, R, Khan, A. Double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol. 2004;24(5):488–496.CrossRefGoogle Scholar
25.Bradwejn, J, Ahokas, A, Stein, DJ, Salinas, E, Emilien, G, Whitaker, T. Venlafaxine extended-release capsules in panic disorder: Flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry. 2005;187:352–359.CrossRefGoogle ScholarPubMed
26.Liebowitz, MR, Asnis, G, Tzanis, E, Whitaker, T. Venlafaxine XR versus placebo in the short-term treatment of panic disorder. Poster presented at: Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.Google Scholar
27.Pollack, M, Mangano, RM, Entsuah, R, Tzanis, E. Short-term treatment of panic disorder: venlafaxine XR vs paroxetine or placebo. Poster presented at: American Psychiatric Association Annual Meeting; May 21-26, 2005; Atlanta, GA.Google ScholarPubMed
28.Pollack, MH, Lepola, U, Koponen, H, et al.A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety. 2006 August 7; [Epub ahead ofprint]Google Scholar
29.Ballenger, JC. Treatment of anxiety disorders to remission. J Clin Psychiatry. 2001;62(suppl 12):5–9.Google ScholarPubMed
30.Sheehan, DV. The Anxiety Disease. New York, NY: Charles Scribners Sons; 1983.Google Scholar
31.Bandelow, B, Andersen, HF, Dolberg, OT. Escitalopram in the treatment of anxiety symptoms associated with depression. Depress Anxiety. 2006. In press.Google Scholar
32.Shear, MK, Clark, D, Feske, U. The road to recovery in panic disorder: response, remission, and relapse. J Clin Psychiatry. 1998;59(suppl 8):4–8.Google ScholarPubMed
33.Shear, K, Belnap, BH, Mazumdar, S, Houck, P, Rollman, BL. Generalized anxiety disorder severity scale (GADSS): a preliminary validation study. Depress Anxiety. 2006;23:77–82.CrossRefGoogle ScholarPubMed